File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lymphoepithelioma-like carcinoma of the lung: Experience with ten cases

TitleLymphoepithelioma-like carcinoma of the lung: Experience with ten cases
Authors
KeywordsChemotherapy
Lymphoepithelioma
Radiotherapy
Issue Date2004
PublisherInternational Union against Tuberculosis and Lung Disease. The Journal's web site is located at http://www.theunion.org/about-the-journal/about-the-journal.html
Citation
International Journal Of Tuberculosis And Lung Disease, 2004, v. 8 n. 7, p. 890-895 How to Cite?
AbstractOBJECTIVE: Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare form of non-small cell lung cancer predominantly affecting young non-smoking Asians, and there has been only limited experience in its palliative chemotherapy and radiotherapy. We investigated tumour response, time to progression and survival of LELC patients who received such treatment. DESIGN: We prospectively recruited patients with confirmed advanced LELC who were treated with chemoradiotherapy in our unit, a regional tertiary referral centre for lung cancer treatment. RESULTS: There were 10 patients (five males, age 47 ± 9.8 years, median follow-up 22 months) with advanced LELC (respectively 1, 4, and 5 patients at TNM stage IIIA, IIIB and IV) who received systemic chemotherapy and radiotherapy. The primary chemotherapy regimen consisted of 5-fluorouracil/leucovorin/cisplatin. The response rates to 5-fluorouracil/ leucovorin/cisplatin were 60% partial response, 10% stable disease, and 30% progressive disease. Eight patients were also given local radiotherapy. Five patients received salvage chemotherapy when disease progressed after primary chemotherapy. The overall median survival was 23.4 ± 4.7 months. CONCLUSION: The encouraging response to combination chemotherapy with 5-fluorouracil/leucovorin/ cisplatin, although empirical, supports its use with radiotherapy in unresectable lymphoepithelioma-like carcinoma of the lung.
Persistent Identifierhttp://hdl.handle.net/10722/148446
ISSN
2015 Impact Factor: 2.148
2015 SCImago Journal Rankings: 1.381
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHo, JCen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorWong, MPen_HK
dc.contributor.authorWong, MKen_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorIp, MSen_HK
dc.contributor.authorChanYeung, Men_HK
dc.contributor.authorTsang, KWen_HK
dc.date.accessioned2012-05-29T06:13:02Z-
dc.date.available2012-05-29T06:13:02Z-
dc.date.issued2004en_HK
dc.identifier.citationInternational Journal Of Tuberculosis And Lung Disease, 2004, v. 8 n. 7, p. 890-895en_HK
dc.identifier.issn1027-3719en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148446-
dc.description.abstractOBJECTIVE: Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare form of non-small cell lung cancer predominantly affecting young non-smoking Asians, and there has been only limited experience in its palliative chemotherapy and radiotherapy. We investigated tumour response, time to progression and survival of LELC patients who received such treatment. DESIGN: We prospectively recruited patients with confirmed advanced LELC who were treated with chemoradiotherapy in our unit, a regional tertiary referral centre for lung cancer treatment. RESULTS: There were 10 patients (five males, age 47 ± 9.8 years, median follow-up 22 months) with advanced LELC (respectively 1, 4, and 5 patients at TNM stage IIIA, IIIB and IV) who received systemic chemotherapy and radiotherapy. The primary chemotherapy regimen consisted of 5-fluorouracil/leucovorin/cisplatin. The response rates to 5-fluorouracil/ leucovorin/cisplatin were 60% partial response, 10% stable disease, and 30% progressive disease. Eight patients were also given local radiotherapy. Five patients received salvage chemotherapy when disease progressed after primary chemotherapy. The overall median survival was 23.4 ± 4.7 months. CONCLUSION: The encouraging response to combination chemotherapy with 5-fluorouracil/leucovorin/ cisplatin, although empirical, supports its use with radiotherapy in unresectable lymphoepithelioma-like carcinoma of the lung.en_HK
dc.languageengen_US
dc.publisherInternational Union against Tuberculosis and Lung Disease. The Journal's web site is located at http://www.theunion.org/about-the-journal/about-the-journal.htmlen_HK
dc.relation.ispartofInternational Journal of Tuberculosis and Lung Diseaseen_HK
dc.subjectChemotherapyen_HK
dc.subjectLymphoepitheliomaen_HK
dc.subjectRadiotherapyen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshCarcinoma, Non-Small-Cell Lung - Drug Therapy - Pathology - Radiotherapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLung Neoplasms - Drug Therapy - Pathology - Radiotherapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSalvage Therapyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleLymphoepithelioma-like carcinoma of the lung: Experience with ten casesen_HK
dc.typeArticleen_HK
dc.identifier.emailHo, JC:jhocm@hku.hken_HK
dc.identifier.emailWong, MP:mwpik@hkucc.hku.hken_HK
dc.identifier.emailIp, MS:msmip@hku.hken_HK
dc.identifier.authorityHo, JC=rp00258en_HK
dc.identifier.authorityWong, MP=rp00348en_HK
dc.identifier.authorityIp, MS=rp00347en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid15260282-
dc.identifier.scopuseid_2-s2.0-3142656484en_HK
dc.identifier.hkuros97425-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-3142656484&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue7en_HK
dc.identifier.spage890en_HK
dc.identifier.epage895en_HK
dc.identifier.isiWOS:000222630000014-
dc.publisher.placeFranceen_HK
dc.identifier.scopusauthoridHo, JC=7402649981en_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK
dc.identifier.scopusauthoridWong, MP=7403907887en_HK
dc.identifier.scopusauthoridWong, MK=23480818200en_HK
dc.identifier.scopusauthoridOoi, GC=7006176119en_HK
dc.identifier.scopusauthoridIp, MS=7102423259en_HK
dc.identifier.scopusauthoridChanYeung, M=54790582200en_HK
dc.identifier.scopusauthoridTsang, KW=7201555024en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats